Summary
Kathleen Dungan, MD, MPH, from The Ohio State University shares the current availability of GLP-1 agonists and SGLT-2 inhibitor medications and a look at the anticipated future of diabetes pharmacotherapies.
•
Kathleen Dungan, MD, MPH, from The Ohio State University shares the current availability of GLP-1 agonists and SGLT-2 inhibitor medications and a look at the anticipated future of diabetes pharmacotherapies.